0000899243-21-030234.txt : 20210727 0000899243-21-030234.hdr.sgml : 20210727 20210727215812 ACCESSION NUMBER: 0000899243-21-030234 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20210727 FILED AS OF DATE: 20210727 DATE AS OF CHANGE: 20210727 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NELSEN ROBERT CENTRAL INDEX KEY: 0001219042 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119665 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GILLIS STEVEN CENTRAL INDEX KEY: 0001229592 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119663 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burow Kristina CENTRAL INDEX KEY: 0001569248 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119664 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARCH Venture Fund XI, L.P. CENTRAL INDEX KEY: 0001831802 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119668 BUSINESS ADDRESS: STREET 1: 8755 W. HIGGINS ROAD, SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 773-380-6600 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD, SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARCH Venture Partners XI, L.P. CENTRAL INDEX KEY: 0001847567 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119667 BUSINESS ADDRESS: STREET 1: 8755 W HIGGINS RD. STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 7733806600 MAIL ADDRESS: STREET 1: 8755 W HIGGINS RD. STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARCH Venture Partners XI, LLC CENTRAL INDEX KEY: 0001847601 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119666 BUSINESS ADDRESS: STREET 1: 8755 W HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 7733806600 MAIL ADDRESS: STREET 1: 8755 W HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DA32 Life Science Tech Acquisition Corp. CENTRAL INDEX KEY: 0001863294 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 863352988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 551-1600 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-07-27 0 0001863294 DA32 Life Science Tech Acquisition Corp. DALS 0001831802 ARCH Venture Fund XI, L.P. DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 0001847567 ARCH Venture Partners XI, L.P. DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 0001847601 ARCH Venture Partners XI, LLC DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 0001219042 NELSEN ROBERT DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 0001569248 Burow Kristina DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 0001229592 GILLIS STEVEN DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 0 0 1 0 Class B Common Stock Class A Common Stock 5166250 I Through DA32 Sponsor LLC This Form 3 is filed jointly by ARCH Venture Fund XI, L.P. ("AVF"), ARCH Venture Partners XI, L.P. ("AVP LP"), ARCH Venture Partners XI, LLC ("AVP LLC"), Kristina Burow, Robert Nelsen and Steven Gillis (collectively, the "Reporting Persons"). Keith Crandell has direct ownership of Class B Common Stock and is filing his own Form 3 separately. Burow, Crandell, Nelsen and Gillis comprise the investment committee of AVP LLC (the AVP X Committee Members). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. DA32 Sponsor LLC ("Sponsor") is the record holder of the securities reported herein. As a managing member of Sponsor, AVF may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, AVP LP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, AVP LLC may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of the AVP X Committee Members may be deemed to beneficially own securities owned directly by Sponsor. The shares of Class B Common Stock are convertible for shares of the Issuer's Class A Common Stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. The shares of Class B Common Stock beneficially owned by the Reporting Persons include up to 750,000 shares of Class B Common Stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of Class A Common Stock, as described in the Registration Statement. See Exhibit 99.1 - Joint Filer Information, which is incorporated herein by reference and describes in further detail the relationships of the Reporting Persons to the Issuer. See Exhibits 24.1, 24.2, 24.3, 24.4, 24.5 and 24.6 - Powers of Attorney. /s/ Henrikki Harsu, Attorney-in-Fact for ARCH Venture Fund XI, L.P. 2021-07-27 /s/ Henrikki Harsu, Attorney-in-Fact for ARCH Venture Partners XI, L.P. 2021-07-27 /s/ Henrikki Harsu, Attorney-in-Fact for ARCH Venture Partners XI, LLC 2021-07-27 /s/ Henrikki Harsu, Attorney-in-Fact for Robert Nelsen 2021-07-27 /s/ Henrikki Harsu, Attorney-in-Fact for Kristina Burow 2021-07-27 /s/ Henrikki Harsu, Attorney-in-Fact for Steven Gillis 2021-07-27 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT 
                               POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom, or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021
                                        ARCH VENTURE FUND XI, L.P.


                                        By: /s/ Mark McDonnell
                                            ------------------------------------
                                            Name:  Mark McDonnell
                                            Title: Managing Director
EX-24.2 3 attachment2.htm EX-24.2 DOCUMENT 
                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom, or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021
                                        ARCH VENTURE PARTNERS XI, L.P.


                                          By: /s/ Mark McDonnell
                                              ---------------------------------
                                              Name:  Mark McDonnell
                                              Title: Managing Director
EX-24.3 4 attachment3.htm EX-24.3 DOCUMENT 
                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom, or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021
                                        ARCH VENTURE PARTNERS XI, LLC


                                          By: /s/ Mark McDonnell
                                              ----------------------------------
                                              Name:  Mark McDonnell
                                              Title: Managing Director
EX-24.4 5 attachment4.htm EX-24.4 DOCUMENT 
                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021

                                        /s/ Robert Nelsen
                                        -------------------------------
                                        Robert Nelsen
EX-24.5 6 attachment5.htm EX-24.5 DOCUMENT 
                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021

                                        /s/ Kristina Burow
                                        -----------------------------
                                        Kristina Burow
EX-24.6 7 attachment6.htm EX-24.6 DOCUMENT 
                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.    sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.


Dated: July 27, 2021

                                        /s/ Steven Gillis
                                        ----------------------------------
                                        Steven Gillis
EX-99.1 8 attachment7.htm EX-99.1 DOCUMENT 
                            Joint Filer Information

Name of Joint Filer:                    ARCH Venture Fund XI, L.P.

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010

Relationship of Joint Filer to
Issuer:                                 10% Owner

Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021


Name of Joint Filer:                    ARCH Venture Partners XI, L.P.

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010


Relationship of Joint Filer to
Issuer:                                 10% Owner

Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021


Name of Joint Filer:                    ARCH Venture Partners XI, LLC

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010

Relationship of Joint Filer to
Issuer:                                 10% Owner

Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021


Name of Joint Filer:                    Robert Nelsen

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010

Relationship of Joint Filer to
Issuer:                                 10% Owner

Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021


Name of Joint Filer:                    Kristina Burow

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010

Relationship of Joint Filer to
Issuer:                                 10% Owner


Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021


Name of Joint Filer:                    Steven Gillis

Address of Joint Filer:                 DA32 Life Science Tech Acquisition Corp.
                                        345 Park Avenue South, 12th Floor
                                        New York, NY 10010

Relationship of Joint Filer to
Issuer:                                 10% Owner

Issuer Name and Ticker or Trading
Symbol:                                 DA32 Life Science Tech Acquisition Corp.
                                        [DALS]

Date of Event Requiring Statement:
(Month/Day/Year):                       07/27/2021